Following the COVID-19 pandemic, researchers observed an increase in type 2 diabetes among adolescents. Experts, including Katie O’Sullivan, MD, presented three strategies to help address the disease in youths: mobilize an interdisciplinary team, explore medical or surgical treatments, and provide community intervention programs.
Priya Prahalad, MD, PhD, previews a presentation at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28.
A forthcoming consensus statement on PROs looks beyond numbers associated with diabetes—glucose levels, A1C, time in range—to the myriad ways the disease affects daily life. Because diabetes relies on the patient’s own engagement in therapeutic behaviors, integrating PROs into clinical models for care is crucial, explained the authors, including Jennifer L. Sherr, MD, PhD.
The debate continues over using beta-cell replacement or automated insulin delivery in the treatment of patients with type 1 diabetes. Michael R. Rickels, MD, MS, presented support for the biological solution provided by islet transplantation, while Bruce A. Buckingham, MD, presented data supporting the artificial pancreas.
Michael Riddell, PhD, and Lori M. Laffel, MD, MPH, provided insight into the unique needs of athletes—children and adults—who live with type 1 diabetes. Different forms of exercise affect glycemia differently, making it important for the type, duration, and intensity of exercise to be factored into the athlete’s care plan.
Filip K. Knop, MD, PhD, previews a presentation at the 83rd Scientific Sessions. Registered participants can view select recordings, including of this session, on the meeting’s virtual platform through August 28.
A1C has long been the gold standard for assessing glycemic control in diabetes over time, but continuous glucose monitoring (CGM) metrics such as time in range (TIR) are increasingly becoming popular because they represent real-time results. Revital Nimri, MD, and other experts discussed the role of TIR and other CGM metrics that use the most…
Growing evidence indicates SGLT2 inhibitors and GLP-1 receptor agonists have beneficial effects not only in patients with type 2 diabetes but also those at risk for cardiovascular disease. Physicians and scientists, including Darren K. McGuire, MD, MHSc, presented findings from trials that demonstrate positive clinical outcomes.
Cancer immunotherapy, monogenic primary immune deficiencies, and celiac disease may have pathologic links to type 1 diabetes. Four experts, including Arabella Young, PhD, discussed ways these conditions may be linked, and in some cases how they can be screened for together.
More than 3 million Americans use continuous glucose monitoring, which provides a plethora of useful data for clinicians. Obtaining and interpreting that data continues to present challenges. Rebecca Rick Longo, MSN, ACNP-BC, CDCES, offered solutions for efficiently downloading the data, and Cari Berget, MPH, RN, CDCES, explained a three-step process for reviewing and using the…